Nothing Special   »   [go: up one dir, main page]

BRPI1011502A2 - composto, pró-droga, medicamento, método para a profilaxia ou tratamento de um sintoma do trato urinário inferior, obesidade, e/ou prolapso de órgão em um mamífero, e, uso do composto. - Google Patents

composto, pró-droga, medicamento, método para a profilaxia ou tratamento de um sintoma do trato urinário inferior, obesidade, e/ou prolapso de órgão em um mamífero, e, uso do composto.

Info

Publication number
BRPI1011502A2
BRPI1011502A2 BRPI1011502A BRPI1011502A BRPI1011502A2 BR PI1011502 A2 BRPI1011502 A2 BR PI1011502A2 BR PI1011502 A BRPI1011502 A BR PI1011502A BR PI1011502 A BRPI1011502 A BR PI1011502A BR PI1011502 A2 BRPI1011502 A2 BR PI1011502A2
Authority
BR
Brazil
Prior art keywords
compound
prodrug
prophylaxis
obesity
mammal
Prior art date
Application number
BRPI1011502A
Other languages
English (en)
Portuguese (pt)
Inventor
Hironobu Maezaki
Izumi Nomura
Shigekazu Sasaki
Tomokazu Kusumoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI1011502A2 publication Critical patent/BRPI1011502A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1011502A 2009-06-15 2010-06-14 composto, pró-droga, medicamento, método para a profilaxia ou tratamento de um sintoma do trato urinário inferior, obesidade, e/ou prolapso de órgão em um mamífero, e, uso do composto. BRPI1011502A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009142673 2009-06-15
PCT/JP2010/060408 WO2010147226A1 (en) 2009-06-15 2010-06-14 Pyrazinooxazepine derivatives

Publications (1)

Publication Number Publication Date
BRPI1011502A2 true BRPI1011502A2 (pt) 2016-03-22

Family

ID=42561089

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011502A BRPI1011502A2 (pt) 2009-06-15 2010-06-14 composto, pró-droga, medicamento, método para a profilaxia ou tratamento de um sintoma do trato urinário inferior, obesidade, e/ou prolapso de órgão em um mamífero, e, uso do composto.

Country Status (41)

Country Link
US (4) US9115139B2 (es)
EP (1) EP2442870B1 (es)
JP (2) JP5579262B2 (es)
KR (1) KR101768234B1 (es)
CN (1) CN102458579B (es)
AR (1) AR077094A1 (es)
AU (1) AU2010260847B2 (es)
BR (1) BRPI1011502A2 (es)
CA (1) CA2765239C (es)
CL (1) CL2011003154A1 (es)
CO (1) CO6491037A2 (es)
CR (1) CR20120021A (es)
CY (1) CY1115483T1 (es)
DK (1) DK2442870T3 (es)
DO (1) DOP2011000393A (es)
EA (1) EA021079B1 (es)
EC (1) ECSP12011603A (es)
ES (1) ES2480275T3 (es)
GE (1) GEP20146168B (es)
HK (1) HK1169623A1 (es)
HR (1) HRP20140589T1 (es)
IL (1) IL216761A (es)
JO (1) JO3087B1 (es)
MA (1) MA33430B1 (es)
ME (1) ME01835B (es)
MX (1) MX2011013081A (es)
MY (1) MY157497A (es)
NZ (1) NZ597507A (es)
PE (1) PE20121049A1 (es)
PL (1) PL2442870T3 (es)
PT (1) PT2442870E (es)
RS (1) RS53414B (es)
SG (1) SG176696A1 (es)
SI (1) SI2442870T1 (es)
SM (1) SMT201400080B (es)
TN (1) TN2011000630A1 (es)
TW (2) TW201529584A (es)
UA (1) UA108357C2 (es)
UY (1) UY32707A (es)
WO (1) WO2010147226A1 (es)
ZA (1) ZA201109370B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
WO2010147226A1 (en) * 2009-06-15 2010-12-23 Takeda Pharmaceutical Company Limited Pyrazinooxazepine derivatives
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
JP2014201578A (ja) * 2013-04-09 2014-10-27 武田薬品工業株式会社 線維筋痛症治療剤
JP2014214132A (ja) * 2013-04-26 2014-11-17 武田薬品工業株式会社 ニコチン依存症の予防・治療剤
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2017026538A1 (en) 2015-08-07 2017-02-16 Takeda Pharmaceutical Company Limited Production method of pyrazine
WO2017111178A1 (en) 2015-12-24 2017-06-29 Takeda Pharmaceutical Company Limited Solid preparation
US9985579B2 (en) 2016-04-12 2018-05-29 Preformed Line Products Co. Mounting assembly for mounting a solar panel
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
SE0002754D0 (sv) 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
EP1337518B1 (en) 2000-11-20 2009-06-17 Biovitrum AB (publ) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
AU2002314744A1 (en) 2001-04-17 2002-10-28 Sepracor, Inc. Thiazole and other heterocyclic ligands and use thereof
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
SI1645558T1 (sl) 2002-06-19 2008-10-31 Biovitrum Ab Publ Piperazinilpirazini kot modulatorji serotonin 5-HT2C receptorja
JP4460450B2 (ja) 2002-06-19 2010-05-12 ビオヴィトルム・アクチボラゲット（プブリクト） 新規化合物、その使用および製造法
CA2514547A1 (en) 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited Receptor agonists
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
DK2332921T3 (en) * 2003-06-17 2016-05-09 Arena Pharm Inc 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3benzazepine hydrochloride
EA016558B1 (ru) * 2003-06-17 2012-05-30 Арена Фармасьютикалз, Инк. Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
JP2006056881A (ja) 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
PL1926712T3 (pl) 2005-09-01 2009-12-31 Lilly Co Eli 6-PODSTAWIONE 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINY JAKO AGONIŚCI RECEPTORA 5-HT2c
FR2895259B1 (fr) 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
WO2008108445A1 (ja) 2007-03-07 2008-09-12 Takeda Pharmaceutical Company Limited ベンゾオキサゼピン誘導体およびその用途
WO2009032754A2 (en) 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
WO2009063993A1 (ja) * 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND ITS USE
JP5361733B2 (ja) * 2007-11-15 2013-12-04 武田薬品工業株式会社 ピリドオキサゼピン誘導体およびその用途
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147226A1 (en) * 2009-06-15 2010-12-23 Takeda Pharmaceutical Company Limited Pyrazinooxazepine derivatives

Also Published As

Publication number Publication date
TW201109338A (en) 2011-03-16
CL2011003154A1 (es) 2012-06-15
AU2010260847B2 (en) 2016-11-24
ME01835B (me) 2014-12-20
EP2442870A1 (en) 2012-04-25
DOP2011000393A (es) 2012-02-15
GEP20146168B (en) 2014-09-25
MX2011013081A (es) 2012-01-20
AU2010260847A1 (en) 2012-01-19
US20110282054A1 (en) 2011-11-17
CA2765239C (en) 2018-08-07
PE20121049A1 (es) 2012-08-22
PL2442870T3 (pl) 2014-12-31
MY157497A (en) 2016-06-15
RS53414B (en) 2014-12-31
JO3087B1 (ar) 2017-03-15
WO2010147226A1 (en) 2010-12-23
PT2442870E (pt) 2014-07-16
ZA201109370B (en) 2012-10-31
JP5579262B2 (ja) 2014-08-27
ES2480275T3 (es) 2014-07-25
SMT201400080B (it) 2014-09-08
HRP20140589T1 (hr) 2014-08-01
AR077094A1 (es) 2011-08-03
SI2442870T1 (sl) 2014-07-31
IL216761A (en) 2016-03-31
CN102458579B (zh) 2014-11-05
CO6491037A2 (es) 2012-07-31
ECSP12011603A (es) 2012-03-30
US8318722B2 (en) 2012-11-27
KR20120034734A (ko) 2012-04-12
HK1169623A1 (en) 2013-02-01
CA2765239A1 (en) 2010-12-23
EA021079B1 (ru) 2015-03-31
JP2012107032A (ja) 2012-06-07
DK2442870T3 (da) 2014-06-30
US20120135979A1 (en) 2012-05-31
TWI542592B (zh) 2016-07-21
JP2012530051A (ja) 2012-11-29
MA33430B1 (fr) 2012-07-03
CY1115483T1 (el) 2017-01-04
US8314088B2 (en) 2012-11-20
EA201270017A1 (ru) 2012-07-30
UA108357C2 (xx) 2015-04-27
US8324201B2 (en) 2012-12-04
JP5579203B2 (ja) 2014-08-27
TW201529584A (zh) 2015-08-01
EP2442870B1 (en) 2014-04-16
CR20120021A (es) 2012-03-06
UY32707A (es) 2011-01-31
TN2011000630A1 (en) 2013-05-24
US20110288291A1 (en) 2011-11-24
KR101768234B1 (ko) 2017-08-14
IL216761A0 (en) 2012-02-29
NZ597507A (en) 2013-09-27
CN102458579A (zh) 2012-05-16
US20100317651A1 (en) 2010-12-16
US9115139B2 (en) 2015-08-25
SG176696A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
BRPI1011502A2 (pt) composto, pró-droga, medicamento, método para a profilaxia ou tratamento de um sintoma do trato urinário inferior, obesidade, e/ou prolapso de órgão em um mamífero, e, uso do composto.
NO2023017I1 (no) Mitapivat or a pharmaceutically acceptable salt thereof, in particular mitapivat sulfate
BRPI0911987A2 (pt) suturas e métodos heterofuncionais codificados.
BRPI1016199A2 (pt) cobertura de ferimento e kit de tratamento de ferimentos.
IL216263A0 (en) Devices, methods and kits for forming tracts in tissue
EP2491899A4 (en) DEVICE FOR DETERMINING DEFECUTION AND MICTION
BRPI1012929A2 (pt) válvula, e, mecanismo de acionamento melhorado.
BRPI0907162A2 (pt) Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero
IL210754A0 (en) Devices, methods, and kits for forming tracts in tissue
BRPI0912245A2 (pt) composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
BR112012008058A2 (pt) implantes e modelos ortopédicos específicos para o paciente.
BRPI1008692A2 (pt) moléculas de anticorpos tendo especificidade para ox40 humano.
BRPI1014901A2 (pt) reduzindo erros médicos.
BRPI1009004A2 (pt) método para integrar diagnóstico e tratamento para tecidos internos, e, sistema para integrar diagnóstico e tratamento para tecidos internos
BRPI1005995A2 (pt) implemento médico para manipular suturas, particularmente útil em cirurgia artroscópia
LT2240137T (lt) Įrenginys, skirtas nutukimo gydymui
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0910737A2 (pt) composto, pró-droga, agente farmacêutico, método para profilaxia ou tratamento de doenças do trato urinário inferior em um mamífero, e, uso de um composto ou uma pró-droga do mesmo.
IL218780A0 (en) Devices,, methods, and kits for forming tracts in tissue
PL2158882T3 (pl) Urządzenie do zapobiegania i leczenia wypadania narządów miednicy
IL202674A0 (en) Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
BR112012015823A2 (pt) dispositivo para incontinência urinária descartável
BRPI0909818A2 (pt) métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
BRPI1007779A2 (pt) perexilina, método para tratamento de hcm, programa de tratamento para tratar hcm e uso da perexilina
BRPI0807980A2 (pt) Polímero de não-polialfaolefinas dispersos para redução de arraste

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements